EICHORPublic-registry trials using Metformin that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Metformin appears in 1 registered trial Eichor's radar has found, sponsored by Intarcia Therapeutics, the most recent registered as Phase 3, with a planned enrollment of 136. Registered timeline: 2015–2017. The registry holds 11,826 registered studies for Diabetes Mellitus, Type 2.
| Trial | Sponsor | Condition | Phase | Sites |
| Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide | Intarcia Therapeutics | Diabetes Mellitus, Type 2 | PHASE3 | 36 |
| Status | Completed · planned start 2015-12 |
| Primary completion | 2017-10 |
| Enrollment target | 136 participants |
| Design | Randomized · Parallel · Phase 3 · 2 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 36 listed in United States |
All fields verbatim from the ClinicalTrials.gov record for NCT02638805.
| First FDA approval | GLUCOPHAGE — March 1995 (application NDA020357, currently held by EMD SERONO INC) |
| Approved applications | 174 — a multi-source (generic) drug |
| Forms & routes | Tablet, Extended Release, Tablet, Solution, For Suspension, Extended Release · Oral |
| Registry-wide use | 3,094 registered studies all-time · 176 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
The public registry holds 11,826 registered studies for Diabetes Mellitus, Type 2. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Diabetes Mellitus, Type 2 studies · Weekly briefs
